Chao H. Huang, MD FACP

Professional Background

I precept and teach medical students, residents and fellows in the field of clinical hematology and medical oncology, with a focus on diagnosis, work up and clinical management, preferring clinical trials. I have a special interest in the field of lung cancer and head and neck cancer, especially in multimodality therapy combining radiation with chemotherapy and immunotherapy.

• University Preparatory Studies, Colegio Rosario , Porto Alegre, Rio Grande do Sul
• MD, Medical Doctor , Univ. Fed. de Rio Grande do Sul, Porto Alegre , Rio Grande do Sul
• Internship, Internal Medicine, Presbyterian Medical Center of Univ of Pennsylvania Health, Philadelphia, , PA
• Residency, Internal Medicine , Presbyterian Medical Center University of Pennsylvania Health System, Philadelphia,, PA
• Presbyterian Medical Center University of Pennsylvania Health System , Philadelphia, PA
• Clinical Fellowship, Hematology & Medical Oncology , Fox Chase Cancer Center and Temple University Hospital
• Other, Fox Chase Cancer Center and Temple University Hospital

• Hematology , American Board of Hematology
• Internal Medicine , American Board Of Internal Medicine
• Kansas License , Kansas
• Medical Oncology , American Board of Medical Oncology
• Pennsylvania, Pennsylvania

• Member American Society of Hematology, Member, 2003 - Present
• Southwest Oncology Group, Member, 2003 - Present
• American Society of Clinical Oncology, Member, 1999 - Present
• Member American Association for Cancer Research , Member, 1998 - Present
• American College of Physicians, Member, 1994 - Present

---

• S1800A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) versues Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (lung-MAP Non-matched Sub-Study), SWOG-NCI, PI
• Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC), Alliance for Clinical Trials in Oncology, PI
• Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers, ECOG, PI
• A Phase 3, Controlled, Open-label Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma, EpicentRx, PI
• A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma, Trizell, PI

• Islam K.M., Deviany Poppy E, Anggondowati Trisari, Ryan June E, Fetrick Ann, Bagenda Danstan, Copur Mehmet S, Tolentino Addison, Vaziri Irfan, McKean Heidi A, Dunder Steven, Gray Jhanelle E, Huang Chao M.D, Ganti Apar Kishor. 2019. Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer. Journal of Oncology Practice, 15 (9), e758-e768. http://dx.doi.org/10.1200/jop.18.00734
• Huang Chao H. 2019. Lung Cancer: Lung Cancer Regional Snapshot Kansas City VA Medical Center. Federal Practitioner
• 2018. Randomized Phase 2 Study of Tivantinib Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer. Lung Cancer (117), 44-49
• Park John, McPike Veronica, Kambhampati Suman, Huang Chao, Fields-Meehan January, Verkruyse Linda, Allen Ace, Reddy Eashwer. 2018. Positivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA. Fed Pract.. https://www.mdedge.com/fedprac/avaho/article/166785/head-neck-cancers/positivity-rates-oropharyngeal-and-nonoropharyngeal
• Komiya Takefumi, Huang Chao H. 2018. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2, 3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. Frontier Oncology. https://doi.org/10.3389/fonc.2018.00423
• Gerber David E, Socinski Mark A, Neal Joel W, Wakelee Heather A, Shirai Keisuke, Sequist Lecia V, Rosovsky et al. Rachel P. 2018. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer, 117, 44-49
• Weng Fen, Sood Sumit, Yap Wendall, Madan Rashna, TenNapel Mindi, Shen Xinglei, Huang Chao H, Chen Allen. 2018. Early-Stage Lung Adenocarcinoma treated with Stereotactic Body Radiation Therapy (SBRT)
• Haque Inamul, Motes Hannah, Sharma Mukut, Borrego Emma, Reyes Diaz, Godwin Andrew K, Huang Chao H. 2018. - Modulation of microRNA expression in EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cell lines. Proceedings of the American Association for Cancer Research Y Volume 59 Y April 2018